Clinical and commercial GMP oligonucleotide drug substance
GMP manufacturing of oligonucleotide drug substance for clinical trials and commercial supply: batch records, validated release and stability methods, change control, and documentation packages suitable for regulatory filing — described at capability level without inventing facility certifications.
GMP
drug substance grade
CPP
controlled processes
CoA / COC
release documentation
ICH
Q7 / Q series
ASO / siRNA
modalities
GMP oligo drug substance scope
GMP batches are manufactured under quality systems covering personnel, equipment qualification, raw material control, environmental monitoring where aseptic steps exist, and deviation / CAPA management.
Release testing confirms identity, purity, potency surrogate (where defined), residuals, bioburden or sterility as applicable, and conformance to approved specifications. Stability commitments support clinical shelf life and post-approval changes.
Indicative GMP supply milestones
Overlaps with NCE / CMC development; dates are project-specific.
Tech transfer & PQ
Manufacturing
Technology transfer package; equipment fit; engineering batches
Analytics
Method transfer / validation to GMP lab
Stability
Place exhibit / validation lots on stability
Regulatory
Dossier cross-check vs GMP batch records
Clinical GMP campaigns
Manufacturing
Phase-appropriate batch sizes; change control
Analytics
Lot release and stability per approved spec
Stability
Ongoing long-term
Regulatory
Annual report data; comparability after changes
Commercial supply
Manufacturing
Campaign planning; API retest / expiry per stability
Analytics
Ongoing method lifecycle management
Stability
Post-approval commitments
Regulatory
Variation support for site or spec changes
GMP documentation package (examples)
Batch documentation
- Master batch record and executed batch record
- In-process controls and equipment log summaries
- Bill of materials with qualified vendors
- Packaging and labeling records for drug substance
Quality records
- Certificate of analysis and certificate of conformity
- Deviation and investigation summaries (as required for QP release)
- Stability study reports and trending
- Reference standard qualification records
Regulatory
- Drug master file or applicant-provided module 3 excerpts
- Site master file cross-references (when applicable)
- Comparability protocols for post-approval changes
- Audit response packages
Clinical vs commercial expectations
| Element | Early clinical | Late clinical / commercial |
|---|---|---|
| Specification | Phase-appropriate limits | Tight, stability-linked limits |
| Validation | Qualification emphasis | Full process and cleaning validation |
| Stability | Supporting tox/clinical hold | Long-term commitments on multiple lots |
| Supply chain | Single campaign focus | Dual sourcing and inventory strategy |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Typical GMP release tests (drug substance)
Appearance
Reported
Solution or lyophilized cake
Identity
MS / sequence confirm
Method validated
Purity / impurities
HPLC / CE
Individual and total limits
Water content
KF
When lyophilized
Residual solvents
GC
ICH Q3C
Bioburden / endotoxin
Per spec
Non-sterile DS typical; sterile if claimed
Assay
UV / HPLC
Potency surrogate unless bioassay defined
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
What you receive
- GMP drug substance batch meeting approved specification
- Certificate of analysis and conformance
- Executed batch documentation per quality agreement
- Stability commitment letter or protocol reference
- Customs / shipping documentation for clinical imports
- Ongoing lifecycle support under quality agreement
Frequently asked questions
ASO, siRNA duplex, conjugated oligos and selected PMO programs — each quoted with conjugation-specific release tests.
Related
Oligo NCE / CMC Development
Chemistry, manufacturing and controls for oligonucleotide new chemical entities: route scouting on solid-phase synthesizers, impurity fate studies, specification setting, stability protocols and regulatory-ready documentation — without implying a specific plant configuration.
View detailsGalNAc Conjugates
N-acetylgalactosamine (GalNAc) ligands conjugated to siRNA, ASO or antisense payloads route uptake via asialoglycoprotein receptor (ASGPR) on hepatocytes. Tri-antennary GalNAc clusters are the dominant motif for systemic subcutaneous dosing in modern RNAi programs.
View detailsAntisense (ASO)
Single-stranded phosphorothioate-rich ASOs for RNase H–mediated knockdown (gapmers) or sequence-specific binding without degradation (steric blockers). Chemistry, length and modification pattern are chosen to the target transcript, tissue and intended clinical dose.
View detailssiRNA Duplexes
Chemically modified siRNA duplexes for RNAi: antisense (guide) and sense (passenger) strands annealed under controlled conditions. Strand-specific identity, duplex integrity and residual single strands are documented for screening through IND-enabling supply.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.